Supernus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. The SUPN stock yearly return is shown above.
The yearly return on the SUPN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SUPN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|